ArticlebioRxiv : the preprint server for biology2025
Identification of a broad and potent V3 glycan site bNAb targeting an N332
Abstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
37 authors.
Lutz GieselmannLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Andrew T DeLaitschDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Malena RohdeLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Caelan RadfordBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, Washington, 98109, USA.
Johanna WorczinskiLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Anna MomotLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Elvin AhmadovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Judith A BurgerDepartment of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA, USA.
Sharvari DeshpandeVir Biotechnology, San Francisco, CA, USA.
Federico GiovannoniVir Biotechnology, San Francisco, CA, USA.
Davide CortiVir Biotechnology, San Francisco, CA, USA.
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-9140-9850
Meryem Seda ErcanogluLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Philipp SchommersLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Ivelin S GeorgievVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
Anthony P WestDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Jacqueline KnüferLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Ricarda StumpfLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Arne KroidlInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany.
Christof GeldmacherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany.
Lucas MagangaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Wiston WilliamMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Nyanda E NtinginyaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Michael HoelscherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany.
Zhengrong YangDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Qing WeiDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
Matthew RenfrowDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Todd J GreenDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
Jan NovakDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
Marit J van GilsDepartment of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0003-3422-8161
Harry B GristickDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID 0000-0002-1957-2821
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-0725-7138
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, Washington, 98109, USA.ORCID 0000-0003-1267-3408
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pamela J BjorkmanDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Funding
Stuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MCHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WESLEY I. SUNDQUIST · 2022 to 2026
$34.4MDefining the mechanisms of HIV resistance to bNAbs in humansU01AI169385 · NIAID · ROCKEFELLER UNIVERSITY · PI Marina Caskey · 2022 to 2026
$7.8MDefining the impact of glycan-microdomains of the HIV-1 Env glycan shieldR01AI162236 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN, RENFROW, MATTHEW B · 2021 to 2025
$3.6MComplete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
$2.4MGates Foundation INV-002143Gates Foundation INV-036842NIAID NIH HHS P01 AI100148NIAID NIH HHS R01 AI140891NIAID NIH HHS R01 AI162236NIAID NIH HHS U01 AI169385NIAID NIH HHS U54 AI170856
Abstract
Broadly neutralizing antibodies (bNAbs) against HIV-1 can suppress viremia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.